Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Status:
Open
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
NCT#04164082
A031803 is reopened to accrual with implementation of Update 8, effective April 18, 2023.
